Benjamin Herzberg, MD, discusses KRAS-mutant non–small cell lung cancer, upfront biomarker testing, and the emerging RAS inhibitor toolkit on Targeted Talks.
|Videos|July 9, 2015
Effects of SIRT and Bevacizumab on Extrahepatic CRC Metastases
Author(s)Guy Van Hazel, MD
Guy Van Hazel, MD, Medical Oncologist, Mount Hospital and School of Medicine University of Western Australia, discusses the effects of selective internal radiation therapy (SIRT) and bevacizumab on extrahepatic colorectal cancer (CRC) metastases.
Advertisement
Advertisement
Related to this article
Broad oncology bundles falter; experts push smaller surgery/radiation episodes, better navigation, and AI analytics to improve value-based care.
In an interview, Peter Voorhees, MD, discusses his presentation of the CERVINO trial data from the International Myeloma Society meeting.
New analysis tracks life-years gained from blood cancer therapies, revealing breakthrough inflection points, stubborn AML gaps, and inequities in access.
For Prostate Cancer Awareness Month, Herbert Lepor, MD, discusses the leading concerns in managing early prostate cancer and tailoring strategies to the patient based on their risk and goals.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Denosumab Biosimilar Approved For Existing Oncology Indications
2
Plinabulin Receives FDA Fast Track Designation in Post-ICI NSCLC
3
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
4
Tile-Based Radiation Improves Local Control in Resected Brain Metastases
5